Last updated: October 8, 2026
Executive summary: Pharmacyclics LLC v. Sandoz Inc., No. 1:18-cv-00192, was a Hatch-Waxman patent dispute in the U.S. District Court for the District of Delaware involving Sandoz’s abbreviated new drug application for generic ibrutinib, the active ingredient in Imbruvica. Pharmacyclics asserted U.S. Patent Nos. 8,754,090 and 9,340,614. The patents covered ibrutinib compounds and related pharmaceutical use claims. The case was part of a broader wave of ANDA litigation against generic applicants seeking approval to market ibrutinib.
Pharmacyclics LLC v. Sandoz Inc. 1:18-cv-00192: Imbruvica Patent Litigation Summary
What was Pharmacyclics LLC v. Sandoz Inc. about?
Pharmacyclics alleged that Sandoz’s ANDA product would infringe patents covering ibrutinib, a Bruton’s tyrosine kinase inhibitor marketed as Imbruvica. Pharmacyclics was the principal patent owner and developer associated with ibrutinib. Janssen Biotech, a Johnson & Johnson company, commercialized Imbruvica with Pharmacyclics. AbbVie later became a major commercial partner through its acquisition of Pharmacyclics.
The dispute arose under the Hatch-Waxman Act. Sandoz’s ANDA included a Paragraph IV certification asserting that the relevant patents were invalid, unenforceable, or would not be infringed by the proposed generic product. Pharmacyclics responded by filing an infringement action, triggering the statutory 30-month stay on FDA approval of the ANDA under 21 U.S.C. § 355(j)(5)(B)(iii).
| Item |
Case detail |
| Case |
Pharmacyclics LLC v. Sandoz Inc. |
| Civil action |
No. 1:18-cv-00192 |
| Court |
U.S. District Court for the District of Delaware |
| Plaintiff |
Pharmacyclics LLC |
| Defendant |
Sandoz Inc. |
| Product |
Generic ibrutinib |
| Reference drug |
Imbruvica |
| Regulatory pathway |
ANDA under the Hatch-Waxman Act |
| Principal patents asserted |
U.S. Patent Nos. 8,754,090 and 9,340,614 |
| Dispute type |
Paragraph IV patent litigation |
| Therapeutic category |
Oncology and hematology |
What patents protected Imbruvica in the Sandoz case?
The principal patents identified in the action were U.S. Patent Nos. 8,754,090 and 9,340,614.
U.S. Patent No. 8,754,090
The ’090 patent is associated with ibrutinib compounds and pharmaceutical compositions. It issued on July 1, 2014, from an application claiming priority to earlier work on covalent kinase inhibitors. The patent was among the core Orange Book patents asserted by Pharmacyclics against ANDA applicants.
The patent’s commercial significance came from its relationship to ibrutinib itself and to drug compositions containing the active compound. A finding that the ANDA product infringed valid claims could have blocked approval or delayed launch until patent expiration or a settlement-defined entry date.
U.S. Patent No. 9,340,614
The ’614 patent issued on May 17, 2016. It was also directed to ibrutinib-related subject matter and was asserted against Sandoz as part of the patent package protecting Imbruvica.
The ’614 patent formed part of a layered estate rather than an isolated protection point. Pharmacyclics used multiple patents to create separate invalidity and infringement issues. This structure is common in small-molecule oncology litigation because compound, composition, formulation and method-of-use claims can produce different outcomes.
Other ibrutinib patents
Pharmacyclics asserted additional ibrutinib patents against other ANDA applicants in related Delaware actions. Those patents included U.S. Patent Nos. 9,556,146 and 9,556,149. The patent mix varied by defendant and ANDA certification.
The existence of related cases does not mean every patent was asserted against Sandoz in No. 1:18-cv-00192. The Sandoz case should be analyzed based on the patents identified in that docket and the specific ANDA products at issue.
When did the Imbruvica patents expire?
The key ibrutinib patents asserted in the early ANDA cases had statutory patent-term dates generally falling in the second half of the 2020s, subject to patent-term adjustment and any applicable regulatory extensions.
| Patent |
Issue date |
General statutory term position |
Commercial relevance |
| U.S. 8,754,090 |
July 1, 2014 |
December 2026 base term associated with priority filings |
Core ibrutinib protection |
| U.S. 9,340,614 |
May 17, 2016 |
December 2026 base term associated with priority filings |
Additional ibrutinib protection |
| U.S. 9,556,146 |
January 31, 2017 |
December 2026 base term associated with priority filings |
Related Orange Book and litigation estate |
| U.S. 9,556,149 |
January 31, 2017 |
December 2026 base term associated with priority filings |
Related Orange Book and litigation estate |
The precise effective expiration date for a particular patent depends on the patent’s recorded patent-term adjustment, terminal disclaimers and any applicable pediatric exclusivity. FDA Orange Book entries and the individual patent records should control for launch planning. [1][2]
The patent expiration analysis also differs from FDA exclusivity. Imbruvica received new chemical entity exclusivity, but that period expired before the core patent terms. FDA regulatory exclusivity therefore did not independently control the timing of generic entry once the statutory exclusivity period ended.
What was the Paragraph IV challenge in the Sandoz litigation?
Sandoz’s ANDA filing challenged the listed ibrutinib patents through Paragraph IV certifications. In practical terms, Sandoz represented that:
- the listed patents were invalid;
- the patents were not enforceable; or
- the proposed generic ibrutinib product would not infringe the asserted claims.
Pharmacyclics treated the certifications as an artificial act of infringement under 35 U.S.C. § 271(e)(2). The complaint sought the standard Hatch-Waxman remedies, including a declaration of infringement and an order preventing commercial marketing before patent expiration.
Paragraph IV litigation did not mean that Sandoz had begun selling ibrutinib. It created an early judicial test of the patent estate before generic launch. The case also gave Sandoz an opportunity to negotiate a launch date, rather than requiring the company to wait for all listed patents to expire.
What was the litigation timeline?
The material procedural sequence was as follows:
| Date or period |
Event |
| 2017-2018 |
Sandoz submitted an ANDA containing Paragraph IV certifications for generic ibrutinib. |
| February 2018 |
Pharmacyclics filed the Delaware infringement action, No. 1:18-cv-00192. |
| 2018 |
Pharmacyclics litigated the asserted patents and Sandoz’s invalidity and noninfringement defenses. |
| 2018-2019 |
Related ANDA actions were filed against other generic ibrutinib applicants. |
| Subsequent proceedings |
The parties resolved the dispute through a litigation-ending disposition rather than a publicly reported merits judgment establishing broad invalidity of the asserted patent estate. |
The docket should be read together with the settlement and dismissal papers. A dismissal following settlement does not establish that the patents were valid, infringed or enforceable. It establishes that the parties resolved the particular dispute without a final merits determination on all contested claims.
Did the case produce a Paragraph IV judgment?
No publicly reported final merits decision in the Sandoz action established that the asserted patents were invalid across the board or that Sandoz was entitled to launch immediately.
This distinction matters. A Hatch-Waxman complaint can end through:
- a settlement;
- a stipulated dismissal;
- a consent judgment;
- a judgment after trial; or
- a pretrial ruling on claim construction, invalidity or infringement.
Only a merits judgment provides a direct judicial answer on validity and infringement. A settlement-based termination generally produces a negotiated launch date and other contractual restrictions instead.
What was the settlement and generic launch position?
The commercial outcome in ibrutinib litigation was driven by settlements between Pharmacyclics, Janssen and individual generic applicants. Those settlements commonly permitted a generic launch before complete expiration of every later-listed patent but after a negotiated delay period.
Public reports concerning ibrutinib settlements have identified launch dates in the early 2030s for certain generic applicants. The exact date, product scope, manufacturing source and permitted indications depend on the agreement with each ANDA filer. A settlement involving another applicant cannot automatically be applied to Sandoz.
The principal business effect of a settlement was to convert litigation uncertainty into a defined entry date. For Pharmacyclics and its commercial partners, the agreement protected a substantial period of branded sales. For Sandoz, it reduced litigation cost and provided a legally defined route to market if FDA approval was obtained.
What was the FDA and Orange Book status of Imbruvica?
Imbruvica is an FDA-approved ibrutinib product marketed in multiple dosage forms and indications, including certain B-cell malignancies and chronic graft-versus-host disease. The approved products include capsules and tablets, with dosage strength and indication varying by label version. [3]
FDA Orange Book listings for Imbruvica identified patents associated with the drug and its approved uses. Orange Book listing does not itself establish that a patent is valid or infringed. It determines which patents an ANDA applicant must address through a Paragraph III or Paragraph IV certification.
The regulatory consequences were:
- a Paragraph IV notice could trigger patent litigation;
- a timely infringement action could produce a 30-month approval stay;
- FDA approval could occur before the negotiated or adjudicated launch date; and
- commercial marketing could remain restricted by patent rights or settlement terms.
The case therefore involved both patent risk and regulatory timing. FDA approval and permission to launch were separate questions.
How strong was the Pharmacyclics ibrutinib patent estate?
The estate was commercially strong but legally segmented.
Strengths
The estate covered the active compound, drug compositions and therapeutic uses. Multiple patents created overlapping barriers to generic entry. Pharmacyclics also had the advantage of a high-value oncology product with extensive clinical and regulatory investment.
The compound and composition claims were important because they could apply across multiple ibrutinib indications. Method-of-use claims provided additional protection for specific diseases or treatment regimens, although their value depended on the ANDA label and the generic applicant’s proposed use.
Vulnerabilities
The patents faced conventional Paragraph IV challenges, including:
- obviousness;
- anticipation;
- written description;
- enablement;
- claim construction;
- noninfringement; and
- enforceability defenses.
A generic applicant could also attempt a section viii statement to carve out patented indications from its proposed label. The practical impact depended on whether the remaining label still induced infringement and whether the carved-out indications represented a material share of demand.
The estate’s strength therefore could not be measured by patent count alone. The relevant questions were whether the core compound claims survived, whether method-of-use claims matched the generic label, and whether later formulation or dosing patents covered the commercially important product.
What generic entry risks existed for Imbruvica?
The principal generic-entry risks were:
- invalidation of a core compound or composition patent;
- a noninfringement ruling based on the ANDA formulation or label;
- a successful section viii carve-out;
- an unfavorable claim-construction ruling;
- a settlement permitting launch earlier than expected;
- FDA approval of multiple ANDAs near the same date; and
- rapid price erosion after multi-source entry.
Ibrutinib is a small molecule, so biosimilar risk did not apply. Generic competition proceeds through the ANDA pathway, not the biologics license application and biosimilar pathway under the Public Health Service Act.
The highest commercial risk would arise from simultaneous approval of several ANDA products. A single authorized generic or one first-filer launch could produce less severe erosion than coordinated entry by several manufacturers.
Which companies challenged the Imbruvica patents?
Pharmacyclics and Janssen faced a broad group of generic challengers in related Delaware actions. Publicly identified defendants in the broader ibrutinib litigation included Sandoz, Amneal, Dr. Reddy’s Laboratories, Cipla, Zydus, Hetero and Alembic, among others.
Each defendant’s case required separate analysis because the ANDA strength, dosage form, proposed label, certification package and settlement terms could differ. The existence of multiple challenges increased the probability that at least one applicant would reach a negotiated launch arrangement.
How did the Sandoz case affect Imbruvica revenue exposure?
Imbruvica was a multibillion-dollar product for its commercial partners. AbbVie reported global Imbruvica sales of approximately $4.6 billion in 2023, although sales were declining as competition increased and some indications matured. [4]
The Sandoz case did not disclose a standalone revenue exposure figure. The economic risk depended on:
- Sandoz’s potential market share;
- the number of other approved ANDAs;
- the negotiated launch date;
- the scope of the approved generic label;
- payer substitution practices; and
- the price discount at entry.
For a product with several generic challengers, the aggregate exposure is generally more important than the effect of one defendant. A settlement with Sandoz could protect revenue from that applicant while leaving separate exposure from other generic manufacturers.
What is the current legal significance of the case?
Pharmacyclics LLC v. Sandoz Inc. is significant as an example of a coordinated Hatch-Waxman defense of a high-value oncology product. It illustrates four points:
- ibrutinib protection depended on a portfolio, not one patent;
- Paragraph IV certification accelerated the patent dispute;
- a settlement could define generic entry without a merits judgment; and
- FDA approval, patent expiration and commercial launch were separate events.
The case should not be cited as a final adjudication that the asserted patents were valid or infringed unless a specific merits order is identified. Its principal value for business analysis is the negotiated allocation of launch timing and the evidence it provides about the commercial strength of the Imbruvica patent estate.
Key takeaways
- Pharmacyclics sued Sandoz in Delaware over an ANDA for generic ibrutinib.
- The principal asserted patents were U.S. Patent Nos. 8,754,090 and 9,340,614.
- The dispute was a Paragraph IV Hatch-Waxman action.
- The case ended without a publicly reported broad merits ruling invalidating the core ibrutinib patents.
- Related ibrutinib litigation involved multiple generic manufacturers.
- Ibrutinib is a small molecule, so biosimilar rules do not apply.
- Generic entry depended on the Sandoz settlement, FDA approval and the expiration or enforceability of the relevant patents.
- The commercial exposure was material because Imbruvica generated multibillion-dollar annual revenue.
- Patent expiration estimates must be checked against the specific Orange Book entry and patent-term adjustment.
- The settlement did not establish general patent validity or infringement outside the parties and claims covered by the agreement.
FAQs about Pharmacyclics v. Sandoz and Imbruvica
What drug was at issue in Pharmacyclics v. Sandoz?
The drug was ibrutinib, marketed by Pharmacyclics and Janssen as Imbruvica. It is a small-molecule Bruton’s tyrosine kinase inhibitor used in hematologic cancers and certain immune disorders.
Was Sandoz the first generic ibrutinib applicant?
The case number alone does not establish Sandoz’s first-filer status. First-to-file status depends on the ANDA submission record and any forfeiture event under the Hatch-Waxman Act.
Did the Sandoz case invalidate Imbruvica patents?
No publicly reported final merits ruling in the action broadly invalidated the asserted Imbruvica patents. The case ended through a litigation-ending disposition rather than a reported trial judgment resolving all validity issues.
Can a generic manufacturer launch ibrutinib after FDA approval?
FDA approval does not by itself authorize commercial launch when enforceable patent rights or a settlement agreement restrict marketing. Approval and launch eligibility must be analyzed separately.
Are Imbruvica method-of-use patents important after compound patents expire?
Yes. Method-of-use patents can restrict labeled uses, although their practical effect depends on the generic label, indication carve-outs, induced-infringement theories and the share of demand associated with the patented use.
References
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
- United States Patent and Trademark Office. (2024). Patent Center: U.S. Patent Nos. 8,754,090 and 9,340,614. USPTO.
- U.S. Food and Drug Administration. (2024). Imbruvica prescribing information. FDA.
- AbbVie Inc. (2024). 2023 annual report. AbbVie.
- Pharmacyclics LLC v. Sandoz Inc., No. 1:18-cv-00192, U.S. District Court for the District of Delaware, docket materials.
